Gritstone bio Inc banner

Gritstone bio Inc
NASDAQ:GRTS

Watchlist Manager
Gritstone bio Inc Logo
Gritstone bio Inc
NASDAQ:GRTS
Watchlist
Price: 0.0193 USD Market Closed
Market Cap: $2.3m

During the last 3 months Gritstone bio Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on May 16, 2024 by Allen Andrew R , who sold 18.2k USD worth of GRTS shares.

Last Transactions:
Jones Erin
$-10.3k
Jooss Karin
$-10.3k
Hawryluk Matthew
$-6.9k
Economides Vassiliki
$-10.3k
Allen Andrew R
$-18.2k
Economides Vassiliki
$+22.8k
Jones Erin
$-13k
Jones Erin
$-11.1k
Jones Erin
$-11.1k
Jones Erin
$-10.7k
Jones Erin
$-10.7k
Jones Erin
$-10.7k
Jones Erin
$-10.7k
Jones Erin
$-22.7k
Jones Erin
$-22.7k
Rousseau Raphael
$-26.1k
Rousseau Raphael
$-250.7k
Yelensky Roman
$-221k
Rousseau Raphael
$-350.6k
Yelensky Roman
$-221k
Woiwode Thomas
$+5m
Rousseau Raphael
$-107.6k
Clarus Lifesciences Iii, L.p.
$+5m
Simon Nicholas
$+5m
View All Transactions

During the last 3 months Gritstone bio Inc insiders have not bought any shares, and have not sold any shares.

The last transaction was made on May 16, 2024 by Allen Andrew R , who sold 18.2k USD worth of GRTS shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Gritstone bio Inc
Insider Trading Chart

Gritstone bio Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Gritstone bio Inc
Last Insider Transactions

Global
Insiders Monitor

Gritstone bio Inc
Glance View

Market Cap
2.3m USD
Industry
Biotechnology

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 193 full-time employees. The company went IPO on 2018-09-28. The firm discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The firm has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).

GRTS Intrinsic Value
Not Available

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett